Aurinia CEO Peter Greenleaf

Af­ter los­ing race for first to mar­ket in lu­pus nephri­tis, Au­rinia taps Ot­su­ka for vo­closporin li­cens­ing pact abroad

Tiny biotech Au­rinia Phar­ma­ceu­ti­cals is look­ing to slay a gi­ant in Glax­o­SmithK­line’s Benlysta — which just scored a big ap­proval in lu­pus nephri­tis — with its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.